FDA Approves Second RET Inhibitor for NSCLC The FDA has approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
What KRAS Clinical Trials Are Available? What clinical trials are available for lung cancer patients with the KRAS mutation? Two experts discuss. Jyoti D. Patel, MD, Jessica Lin, MD, Terri Conneran
Immunotherapy for Lung Cancer Brings Treatment Breakthroughs David P. Carbone, MD, PhD, Lisa Goldman, Michele Nadeem-Baker
New Targeted Therapies for RET Gene in Lung Cancer Viola Zhu, MD, PhD, Karen Reckamp, MD, Lisa Goldman, Michele Nadeem-Baker
Clinical Trials For EGFR Lung Cancer Alex Spira, MD, PhD, FACP, Bruce E. Johnson, MD, Mike Smith, Jill Feldman, Andrea Hutton
What is the First Line Treatment for EGFR-Mutant NSCLC? Bruce E. Johnson, MD, Alex Spira, MD, PhD, FACP
Why Should Lung Cancer Patients Consider a Clinical Trial? Jessica Wittebort, Lecia Sequist, MD, MPH - DF/HCC, Janet Freeman-Daily, Andrew Schorr
Lung Cancer Treatment Decisions: What If Genetic Tests Don’t Reveal a Driver Mutation? Lecia Sequist, MD, MPH - DF/HCC, Janet Freeman-Daily, Andrew Schorr